Advertisement

Topics

Pluristem Therapeutics Inc. Company Profile

04:59 EST 14th December 2018 | BioPortfolio

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).


News Articles [730 Associated News Articles listed on BioPortfolio]

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Pluristem Therapeutics (PSTI) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Edison Investment Research is terminating coverage on Pluristem Therapeutics (PSTI). Please note you should no longer...

William Prather, of Pluristem Therapeutics, discusses the change in the way pharmaceutical companies look at cell based therapies

In this episode of PharmaTelevision News Review, filmed at BIO 2011, Fintan Walton talks to William R. Prather, Senior Vice President Corporate Development of Pluristem Therapeutics inc.

Pluristem Therapeutics (PSTI) - FY18 results and top-line claudication data

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Pluristem ended FY18 with an operating loss of $33.7m mostly attributed to R&D expenditure ($22.6m) and as of 30 ...

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food and Drug Administra...

Pluristem brings in Thermo Fisher to ‘transform cell therapy manufacturing’

Pluristem Therapeutics has announced that it has agreed a strategic collaboration with Thermo Fisher to improve the process by which cell therapies are manufactured.

Pluristem gets expanded access program for critical limb ischemia drug

Pluristem Therapeutics will initiate an FDA-approved expanded access program for cell product PLX-PAD for the treatment of pa -More- 

Converting medical waste to therapeutics for all: Zami Aberman, CEO and Chairman, Pluristem

In cell therapy the process is the product. Pluristem’s 3D expansion technology allows for the production of different PLX cell products. . Pluristem manufactures therapeutic cell products using hu...

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1285 Associated Companies listed on BioPortfolio]

Pluristem Therapeutics Inc.

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Pluristem Therapeutics Inc." on BioPortfolio

We have published hundreds of Pluristem Therapeutics Inc. news stories on BioPortfolio along with dozens of Pluristem Therapeutics Inc. Clinical Trials and PubMed Articles about Pluristem Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pluristem Therapeutics Inc. Companies in our database. You can also find out about relevant Pluristem Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record